MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.
Under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Vittoria’s technology and clinical programs are designed to address current gaps with contemporary cell therapies and the Company is planning to file an investigational new drug application (IND) for their lead program, Viper 101, later this year. Viper 101 is a gene-edited, autologous, dual-population cell therapy developed from Vittoria’s proprietary Senza5™ platform that addresses significant unmet therapeutic need for the treatment of T-cell lymphoma. Vittoria’s patent-protected Senza5™ platform technology is designed to improve the viability, efficacy, and safety of CAR-T treatments by modulating a novel checkpoint pathway in engineered T-cells. Senza5™ CAR-T cells have demonstrated superior anti-tumor efficacy in both liquid and solid tumor preclinical models and utilize a proprietary five-day manufacturing